Nagy A Habib

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9536611/publications.pdf

Version: 2024-02-01

100 papers	4,639 citations	117625 34 h-index	106344 65 g-index
103 all docs	103 docs citations	103 times ranked	5874 citing authors

#	Article	IF	Citations
1	Targeting chromatin: Transcriptional gene activation (saRNA). , 2022, , 3-16.		0
2	Small Activating RNA Modulation of the G Proteinâ€Coupled Receptor for Cancer Treatment. Advanced Science, 2022, 9, .	11.2	10
3	PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer, 2021, 21, 301.	2.6	42
4	Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. Nature Communications, 2021, 12, 1454.	12.8	20
5	Cannabinoids in the landscape of cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2507-2534.	2.5	53
6	Image-Guided Percutaneous Pancreatic Duct Drainage: A 10-Year Observational Study. Journal of Vascular and Interventional Radiology, 2021, 32, 1075-1080.e2.	0.5	3
7	MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models. International Journal of Molecular Sciences, 2021, 22, 9168.	4.1	10
8	Upregulation of C/EBPÎ± Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. Clinical Cancer Research, 2021, 27, 5961-5978.	7.0	47
9	RNA Activationâ€"A Novel Approach to Therapeutically Upregulate Gene Transcription. Molecules, 2021, 26, 6530.	3.8	15
10	Liver Activation of Hepatocellular Nuclear Factor-4Î± by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile. Molecular Therapy - Nucleic Acids, 2020, 19, 361-370.	5.1	47
11	No difference in mortality among ALPPS, two-staged hepatectomy, and portal vein embolization/ligation: A systematic review by updated traditional and network meta-analyses. Hepatobiliary and Pancreatic Diseases International, 2020, 19, 411-419.	1.3	7
12	Immunological combination treatment holds the key to improving survival in pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2897-2911.	2.5	14
13	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-Î±, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clinical Cancer Research, 2020, 26, 3936-3946.	7.0	86
14	Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics, 2020, 10, 338.	2.6	14
15	Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines, 2020, 8, 247.	4.4	9
16	Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. Molecular Therapy, 2020, 28, 1759-1771.	8.2	177
17	Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. World Journal of Gastroenterology, 2020, 26, 2040-2048.	3.3	13
18	Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, 4601-4601.	1.6	1

#	Article	IF	Citations
19	Targeted Delivery of C/EBPÎ±-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC. Molecular Therapy - Nucleic Acids, 2019, 18, 142-154.	5.1	23
20	Immunomodulatory Changes Following Isolated RF Ablation in Colorectal Liver Metastases: A Case Report. Medicines (Basel, Switzerland), 2019, 6, 56.	1.4	1
21	Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2019, 8, 385.	2.4	21
22	Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. Molecular Therapy, 2019, 27, 999-1016.	8.2	13
23	Developing small activating RNA as a therapeutic: current challenges and promises. Therapeutic Delivery, 2019, 10, 151-164.	2.2	49
24	Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. Hpb, 2019, 21, 773-783.	0.3	31
25	Mechanisms involved in the activation of C/EBPÎ± by small activating RNA in hepatocellular carcinoma. Oncogene, 2019, 38, 3446-3457.	5.9	24
26	An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRÎ± Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Molecular Therapy - Nucleic Acids, 2019, 14, 131-141.	5.1	38
27	Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?. Oncotarget, 2019, 10, 696-706.	1.8	6
28	Unique-region phosphorylation targets LynA for rapid degradation, tuning its expression and signaling in myeloid cells. ELife, 2019, 8, .	6.0	13
29	Abstract 3856: MTLCEBPA, a drug candidate for hepatocellular-carcinoma enhances efficacy of Sorafenib. , 2019, , .		1
30	The journey of radiofrequency-assisted liver resection. Surgical Oncology, 2018, 27, A16-A18.	1.6	3
31	Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene, 2018, 37, 3216-3228.	5.9	60
32	Emerging In Vitro 3D Tumour Models in Nanoparticle-Based Gene and Drug Therapy. Trends in Biotechnology, 2018, 36, 477-480.	9.3	4
33	The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology. Medical Oncology, 2018, 35, 151.	2.5	8
34	Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma. Current Pharmaceutical Biotechnology, 2018, 19, 611-621.	1.6	31
35	Study to evaluate the immunomodulatory effects of radiofrequency ablation compared to surgical resection for liver cancer. Journal of Cancer, 2018, 9, 3187-3195.	2.5	14
36	Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. British Journal of Cancer, 2018, 119, 815-822.	6.4	35

#	Article	IF	Citations
37	Radiofrequency-assisted liver resection: Technique and results. Surgical Oncology, 2018, 27, 415-420.	1.6	10
38	Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-Î± in patients with advanced liver cancer.. Journal of Clinical Oncology, 2018, 36, 2509-2509.	1.6	6
39	Radiofrequency assisted pancreaticoduodenectomy for palliative surgical resection of locally advanced pancreatic adenocarcinoma. Oncotarget, 2018, 9, 15732-15739.	1.8	3
40	Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Oncotarget, 2018, 9, 19006-19013.	1.8	116
41	Will Nanotechnology Bring New Hope for Gene Delivery?. Trends in Biotechnology, 2017, 35, 434-451.	9.3	97
42	Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis. Molecular Cancer Research, 2017, 15, 811-820.	3.4	24
43	Non-alcoholic fatty liver disease: A sign of systemic disease. Metabolism: Clinical and Experimental, 2017, 72, 94-108.	3.4	132
44	A systematic review on radiofrequency assisted laparoscopic liver resection: Challenges and window to excel. Surgical Oncology, 2017, 26, 296-304.	1.6	9
45	Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. Molecular Therapy - Nucleic Acids, 2017, 6, 80-88.	5.1	65
46	Limitations in Clinical Translation of Nanoparticle-Based Gene Therapy. Trends in Biotechnology, 2017, 35, 1124-1125.	9.3	15
47	Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer. Molecular Therapy, 2017, 25, 2705-2714.	8.2	76
48	Recent Development of Augmented Reality in Surgery: A Review. Journal of Healthcare Engineering, 2017, 2017, 1-9.	1.9	244
49	Impact of cavitron ultrasonic surgical aspirator (CUSA) and bipolar radiofrequency device (Habib-4X) based hepatectomy for hepatocellular carcinoma on tumour recurrence and disease-free survival. Oncotarget, 2017, 8, 93644-93654.	1.8	16
50	Treatment of Liver Cancer by C/EBPA saRNA. Advances in Experimental Medicine and Biology, 2017, 983, 189-194.	1.6	7
51	First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-Î± in patients with advanced liver cancer.. Journal of Clinical Oncology, 2017, 35, TPS2612-TPS2612.	1.6	2
52	Targeted Delivery of C/EBPÎ± -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo. Molecular Therapy, 2016, 24, 1106-1116.	8.2	53
53	Oncological Outcomes of Major Liver Resection Following Portal Vein Embolization: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2016, 23, 3709-3717.	1.5	38
54	C/EBPÎ± Short-Activating RNA Suppresses Metastasis of Hepatocellular Carcinoma through Inhibiting EGFR/Î²-Catenin Signaling Mediated EMT. PLoS ONE, 2016, 11, e0153117.	2.5	30

#	Article	IF	Citations
55	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget, 2016, 7, 28556-28569.	1.8	19
56	Identification of Cellular Targets of MicroRNA-181a in HepG2 Cells: A New Approach for Functional Analysis of MicroRNAs. PLoS ONE, 2015, 10, e0123167.	2.5	9
57	Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World Journal of Gastrointestinal Surgery, 2015, 7, 52.	1.5	194
58	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. European Journal of Cancer, 2015, 51, 1389-1404.	2.8	94
59	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Lancet, The, 2015, 385, S37.	13.7	54
60	Analysis of Endoscopic Radiofrequency Ablation of Biliary Malignant Strictures in Pancreatic Cancer Suggests Potential Survival Benefit. Digestive Diseases and Sciences, 2015, 60, 3449-3455.	2.3	105
61	Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharmaceutica Sinica B, 2015, 5, 194-200.	12.0	30
62	Endoscopic ultrasound-guided lymph node ablation with a novel radiofrequency ablation probe: feasibility study in an acute porcine model. Endoscopy, 2014, 46, 411-415.	1.8	22
63	Technical Development of a New Semispherical Radiofrequency Bipolar Device (RONJA):Ex VivoandIn VivoStudies. BioMed Research International, 2014, 2014, 1-7.	1.9	1
64	MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. Gastroenterology, 2014, 146, 268-277.e18.	1.3	141
65	Exploiting Human CD34+ Stem Cellâ€“conditioned Medium for Tissue Repair. Molecular Therapy, 2014, 22, 149-159.	8.2	7
66	Intra-Arterial Immunoselected CD34+ Stem Cells for Acute Ischemic Stroke. Stem Cells Translational Medicine, 2014, 3, 1322-1330.	3.3	131
67	Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesisin vivo. Hepatology, 2014, 59, 216-227.	7.3	92
68	Safety and Efficacy of Radiofrequency Ablation in the Management of Unresectable Bile Duct and Pancreatic Cancer: A Novel Palliation Technique. Journal of Oncology, 2013, 2013, 1-5.	1.3	104
69	Gene Expression Profile Changes After Short-activating RNA-mediated Induction of Endogenous Pluripotency Factors in Human Mesenchymal Stem Cells. Molecular Therapy - Nucleic Acids, 2012, 1, e35.	5.1	28
70	Autologous Bone Marrow Stem Cells in the Treatment of Chronic Liver Disease. International Journal of Hepatology, 2012, 2012, 1-7.	1.1	19
71	Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of the Pancreas in a Porcine Model. Gastroenterology Research and Practice, 2012, 2012, 1-6.	1.5	74
72	A perspective on non-catalytic Src homology (SH) adaptor signalling proteins. Cellular Signalling, 2012, 24, 388-392.	3.6	20

#	Article	IF	Citations
73	Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointestinal Endoscopy, 2011, 73, 149-153.	1.0	289
74	Endoscopic Radiofrequency Ablation in Colorectal Cancer. Diseases of the Colon and Rectum, 2009, 52, 355-358.	1.3	21
75	Autologous Infusion of Expanded Mobilized Adult Bone Marrow-Derived CD34+ Cells Into Patients With Alcoholic Liver Cirrhosis. American Journal of Gastroenterology, 2008, 103, 1952-1958.	0.4	195
76	The Use of Mesenchymal Stem Cells for Bone and Cartilage Repair. , 2008, , 269-294.		0
77	The Meritocracy of Stem Cells for Therapy. , 2008, , 1-5.		0
78	Radiofrequency-Assisted Liver Resection. , 2008, , 551-567.		2
79	Adult Human Stem Cell Therapy for Ischaemic Stroke. , 2008, , 181-197.		0
80	Liver Repair. , 2008, , 619-631.		0
81	Impact of radiofrequency assisted hepatectomy for reduction of transfusion requirements. American Journal of Surgery, 2007, 193, 143-148.	1.8	42
82	Haemostasis in Liver Surgery. , 2007, , 153-164.		2
83	Characterization and Clinical Application of Human CD34 ⁺ Stem/Progenitor Cell Populations Mobilized into the Blood by Granulocyte Colonyâ€Stimulating Factor. Stem Cells, 2006, 24, 1822-1830.	3.2	267
84	The Isolation and Characterisation of CD34 Positive Cells from the Human Adult Liver. Clinical Science, 2003, 104, 21P-21P.	0.0	0
85	New Technique for Liver Resection Using Heat Coagulative Necrosis. Annals of Surgery, 2002, 236, 560-563.	4.2	252
86	Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Therapy, 2002, 9, 254-259.	4.6	120
87	Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus. Cancer Gene Therapy, 2002, 9, 414-420.	4.6	30
88	Adenovirus replicationâ€“competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Therapy, 2002, 9, 651-654.	4.6	20
89	Intravascular Micropump for Augmented Liver Perfusion: First In Vivo Experience. Artificial Organs, 2001, 25, 392-394.	1.9	8
90	The cytotoxic effect of E1B 55-kDa mutant adenovirus on human hepatocellular carcinoma cell lines. Cancer Gene Therapy, 2001, 8, 333-341.	4.6	10

#	Article	IF	Citations
91	E1B-Deleted Adenovirus (dl1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors. Human Gene Therapy, 2001, 12, 219-226.	2.7	113
92	Microsatellite Instability And Allelic Imbalance In Primary And Secondary Colorectal Cancer. Australian and New Zealand Journal of Surgery, 2000, 70, 587-592.	0.2	12
93	Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules. Cancer Gene Therapy, 2000, 7, 456-465.	4.6	15
94	Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after ad-p53 treatment. Hepatology, 2000, 31, 885-889.	7.3	44
95	The effect of mechanically enhancing portal venous inflow on hepatic oxygenation, microcirculation, and function in a rabbit model with extensive hepatic fibrosis. Hepatology, 1999, 30, 46-52.	7.3	14
96	Total vascular exclusion for liver resections: Pros and cons. , 1999, 72, 50-55.		15
97	The use of hypothermia and circulatory arrest to control intraoperative bleeding from the inferior vena cava. Surgery Today, 1996, 26, 217-218.	1.5	6
98	Partial characterization of a cDNA for human stearoyl-CoA desaturase and changes in its mRNA expression in some normal and malignant tissues. International Journal of Cancer, 1994, 57, 348-352.	5.1	119
99	Augmented portal flow in the isolated perfused cirrhotic rat liver: a haemodynamic and morphological study. Clinical Science, 1993, 84, 185-192.	4.3	11
100	Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. , 0, .		2